Back to results
US 2025/0059609 A1Published application
Biomarkers for the identification of aggressive prostate cancer and methods of treatment thereof
AssigneeDuke University
InventorsQing CHENG, Jiaoti HUANG
Life of this patent
Estimating the term…
Abstract
The present disclosure describes, in part, biomarkers for the identification of aggressive prostate cancer by determining a castration-resistant prostate cancer (CRPC) evolutionary signature of prostate cells, and methods of use thereof.
Claims20
A method of determining the risk of disease progression of prostate cancer in a subject, the method comprising:
- (i) obtaining a biological sample from the subject, said sample comprising prostate cancer cells;
- and
- (ii) determining a castration-resistant prostate cancer (CRPC) evolutionary signature of the prostate cancer cells to generate a score,
- wherein a sample having a high score as compared to a control is indicative of aggressive prostate cancer.
1 more element
A method of detecting and treating an aggressive prostate cancer in a subject, the method comprising:
- (i) obtaining a biological sample from the subject, said sample comprising prostate cancer cells;
- (ii) determining a castration-resistant prostate cancer (CRPC) evolutionary signature in the sample to generate a score, in which samples from the subject have a higher score as compared to a control, which higher score is indicative of the aggressive prostate cancer;
- and then
- (iii) administering a prostate cancer treatment to the subject determined to have aggressive prostate cancer.
1 more element
-23. (canceled)
Dependencies are inferred from the claim text.